SCHEMBL6774285

SCHEMBL6774285

CCOCn1nnc(-c2ccc(F)cc2)c1-c1ccnc(OCCOC)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 15/20 0.58
BRD4 O60885 1/20 0.40
MAPK13 O15264 4/20 0.39
MAPK12 P53778 4/20 0.39
MAPK11 Q15759 4/20 0.39
PRKD3 O94806 3/20 0.39
MAP4K4 O95819 3/20 0.39
CSNK1A1 P48729 3/20 0.39
CSNK1D P48730 3/20 0.39
MINK1 Q8N4C8 3/20 0.39
PRKCA P17252 2/20 0.39
MAP4K5 Q9Y4K4 2/20 0.39
FRK P42685 2/20 0.39
MAPK9 P45984 2/20 0.39
PRKD2 Q9BZL6 2/20 0.39
KDM4E B2RXH2 1/20 0.39
EGFR P00533 1/20 0.39
RAF1 P04049 1/20 0.39
CYP1A2 P05177 1/20 0.39
LCK P06239 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6779673 0.90 MAPK14 (0.62) MAPK14BRD4MAPK13MAPK12MAPK11
SCHEMBL6772997 0.90 MAPK14 (0.55) MAPK14BRD4MAPK13MAPK12MAPK11
SCHEMBL6772274 0.86 MAPK14 (0.60) MAPK14BRD4
SCHEMBL6775306 0.85 MAPK14 (0.59) MAPK14BRD4MAPK13MAPK12MAPK11
SCHEMBL6768633 0.85 MAPK14 (0.56) MAPK14BRD4CYP1A2
SCHEMBL6775564 0.85 MAPK14 (0.56) MAPK14BRD4CYP1A2CYP2C9CYP2C19
SCHEMBL6768473 0.84 MAPK14 (0.55) MAPK14BRD4MAPK13MAPK12MAPK11
SCHEMBL6775176 0.83 MAPK14 (0.66) MAPK14BRD4MAPK13MAPK12MAPK11
SCHEMBL6624696 0.83 MAPK14 (0.57) MAPK14BRD4
SCHEMBL6769842 0.83 MAPK14 (0.56) MAPK14BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030013712-A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity PROCTER & GAMBLE COMPANY, THE 2003-01-16 US claimed
US-6727364-B2 ANTIINFLAMMATORY AGENTS THE PROCTER & GAMBLE COMPANY 2004-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013712-A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity IL4, IL1A, IL2 MAPK14 3429/4885BRD4 389/4885MAPK13 4097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.